Logo image of NBSE

NEUBASE THERAPEUTICS INC (NBSE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NBSE - US64132K2015 - Common Stock

0.378 USD
-0.01 (-3.2%)
Last: 5/10/2024, 8:08:45 PM
0.42 USD
+0.04 (+11.11%)
After Hours: 5/10/2024, 8:08:45 PM
Fundamental Rating

2

Overall NBSE gets a fundamental rating of 2 out of 10. We evaluated NBSE against 525 industry peers in the Biotechnology industry. While NBSE seems to be doing ok healthwise, there are quite some concerns on its profitability. NBSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year NBSE has reported negative net income.
  • In the past year NBSE had a positive cash flow from operations.
  • NBSE had negative earnings in each of the past 5 years.
  • In the past 5 years NBSE always reported negative operating cash flow.
NBSE Yearly Net Income VS EBIT VS OCF VS FCFNBSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of NBSE (-73.74%) is worse than 69.40% of its industry peers.
  • Looking at the Return On Equity, with a value of -150.22%, NBSE is doing worse than 65.98% of the companies in the same industry.
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROIC N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
NBSE Yearly ROA, ROE, ROICNBSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

  • NBSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBSE Yearly Profit, Operating, Gross MarginsNBSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for NBSE has been increased compared to 1 year ago.
  • Compared to 1 year ago, NBSE has an improved debt to assets ratio.
NBSE Yearly Shares OutstandingNBSE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
NBSE Yearly Total Debt VS Total AssetsNBSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -10.48, we must say that NBSE is in the distress zone and has some risk of bankruptcy.
  • NBSE's Altman-Z score of -10.48 is on the low side compared to the rest of the industry. NBSE is outperformed by 78.97% of its industry peers.
  • There is no outstanding debt for NBSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -10.48
ROIC/WACCN/A
WACCN/A
NBSE Yearly LT Debt VS Equity VS FCFNBSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

  • NBSE has a Current Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.87, NBSE is not doing good in the industry: 68.03% of the companies in the same industry are doing better.
  • NBSE has a Quick Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.87, NBSE is doing worse than 66.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
NBSE Yearly Current Assets VS Current LiabilitesNBSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.05% over the past year.
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.88% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBSE Yearly EPS VS EstimatesNBSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBSE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBSE Price Earnings VS Forward Price EarningsNBSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NBSE indicates a rather cheap valuation: NBSE is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 0.1
EV/EBITDA N/A
NBSE Per share dataNBSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • NBSE's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3Y21.21%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for NBSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUBASE THERAPEUTICS INC / NBSE FAQ

What is the ChartMill fundamental rating of NEUBASE THERAPEUTICS INC (NBSE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NBSE.


Can you provide the valuation status for NEUBASE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 2 / 10 to NEUBASE THERAPEUTICS INC (NBSE). This can be considered as Overvalued.


Can you provide the profitability details for NEUBASE THERAPEUTICS INC?

NEUBASE THERAPEUTICS INC (NBSE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for NBSE stock?

The Earnings per Share (EPS) of NEUBASE THERAPEUTICS INC (NBSE) is expected to decline by -25.75% in the next year.